Moderna (NASDAQ:MRNA) Shares Sold Off Rep. Maria Elvira Salazar

Posted by Kim Johansen on Sep 12th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $7.35 during mid-day trading on Friday, hitting $143.97. The company had a trading volume of 15,383,796 shares, compared to its average volume of 33,437,252. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The firm has a market cap of $57.48 billion, a P/E ratio of -18.02 and a beta of 1.10. The business’s 50-day simple moving average is $92.35 and its 200-day simple moving average is $66.74. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($2.13) earnings per share. As a group, analysts predict that Moderna, Inc. will post -6.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MRNA. Integrated Wealth Concepts LLC grew its position in Moderna by 17.0% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,653 shares of the company’s stock worth $536,000 after acquiring an additional 1,114 shares during the last quarter. NewEdge Advisors LLC boosted its stake in Moderna by 208.0% in the second quarter. NewEdge Advisors LLC now owns 4,364 shares of the company’s stock worth $306,000 after purchasing an additional 2,947 shares in the last quarter. Baird Financial Group Inc. grew its holdings in shares of Moderna by 149.3% during the second quarter. Baird Financial Group Inc. now owns 11,918 shares of the company’s stock worth $835,000 after purchasing an additional 7,137 shares during the last quarter. Waverly Advisors LLC bought a new stake in shares of Moderna during the second quarter worth $243,000. Finally, Murphy Pohlad Asset Management LLC acquired a new stake in shares of Moderna in the second quarter valued at $268,000. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.80% of the company’s stock.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Rothschild & Co Redburn cut Moderna from a “neutral” rating to a “sell” rating and boosted their price objective for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Morgan Stanley increased their price target on shares of Moderna from $39.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 20th. Finally, The Goldman Sachs Group raised their price target on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 19th. Seven investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $76.72.

Get Our Latest Stock Report on MRNA

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.